Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-09
2007-10-09
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S231500, C514S255030, C514S318000, C514S326000, C540S467000, C544S124000, C544S360000, C546S187000, C546S194000, C546S208000
Reexamination Certificate
active
10692080
ABSTRACT:
Substituted phenylpiperidines and phenylpyrrolidines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
REFERENCES:
patent: 3714179 (1973-01-01), Tweit
patent: 3886160 (1975-05-01), Tweit
patent: 4659716 (1987-04-01), Villani et al.
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5217986 (1993-06-01), Pomponi et al.
patent: 5352707 (1994-10-01), Pompni et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 2005/0222408 (2005-10-01), Lee et al.
patent: 0 952 154 (1999-10-01), None
patent: 0978512 (2000-02-01), None
patent: 1 074 543 (2001-02-01), None
patent: 02306237 (1990-12-01), None
patent: WO99/42458 (1999-08-01), None
patent: WO 02/012190 (2002-02-01), None
patent: WO 02/012214 (2002-02-01), None
patent: WO 02/024695 (2002-03-01), None
patent: WO 02/076925 (2002-10-01), None
patent: WO 03/047520 (2003-06-01), None
patent: WO 03/050099 (2003-06-01), None
patent: WO 03/053912 (2003-07-01), None
patent: WO 03/066604 (2003-08-01), None
Apodaca et al. Preparation of phenylpiperidines . . . CA 140:375080 (2004).
PCT International Search Report, dated Mar. 29, 2004, for PCT Int'l Appln. No. PCT/US03/33809.
Albengres, E. et al. Systemic Antifungal Agents. Drug Safety (Feb. 1998) 18(2):83-97.
Ali, S.M. et al. Design, Synthesis, and Structure-Activity Relationships of Acetylene-Based Histamine H3 Receptor Antagonists. J. Med. Chem. (1999) 42(5):903-909.
Arrang, J.-M. et al. Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor. Nature (Apr. 1983) 302:832-837.
Ash, A.S.F.; Schild, H.O. Receptors Mediating Some Actions of Histamine. Br. J. Pharmac, Chemother. (1966) 27:427-439.
Back, D.J.; Tjia, J.F. Inhibition of Tolbutamide Metabolism by Substituted Imidazole Drugs In Vivo: Evidence for a Structure-Activity Relationship. Br. J. Pharmacol. (1985) 85:121-126.
Barnes, J.C. et al. The Selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release In Vivo. Soc. Neurosci. Abstr. (1993) 19:1813.
Bioworld Today, Mar. 2, 1999, p. 3.
Black, J.W. et al. Definition and Antagonism of Histamine H2-Receptors. Nature (Apr. 1972) 236:385-390.
Ding, Y.-S. et al. Synthesis of High Specific Activity (+)- and (-)-6-[18F]Fluoronorepinephrine via the Nucleophilic Aromatic Substitution Reaction. J. Med. Chem. (1991) 34(2):767-771.
Ganellin, C.R. et al. Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists. Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.) (1998) 331:395-404.
Garbarg, M. et al. S-[2-(4-Imidazolyl)ethyl]isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist. J. Pharmacol. Exp. Ther. (1992) 263(1):304-310.
Gliatech Inc. Press Release Nov. 5, 1998.
Gonzalez, F. Garcia, et al. Synthesis of 3-aryl(alkyl)-4(D-arabino-tetrahydroxybutyl)imidazoline-2-thiones. Carbohydrate Research, 22(2), 436-40 (English) 1968.
Ichinose, M.; Barnes, P.J. Histamine H3-Receptors Modulate Nonadrenergic Noncholinergic Neural Bronchoconstriction in Guinea-Pig In Vivo. Eur. J. Pharmacol. (1989) 174(1):49-55.
Imamura, M. et al. Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release. J. Pharmacol. Exp. Ther. (1994) 271(3):1259-1266.
Jones, R.G. Studies on Imidazoles. II. The Synthesis of 5-Imidazolecarboylates fromGlycine and Substituted Glycine Esters. J. Am. Chem. Soc. (1949) 71:644-647.
Jordaan, A., Arndt, R.R., The Synthesis of 1-Methyl-5-(α-indolyl)imidazole and 1-Methyl-2-ethylthiol-5-(α-indolyl)imidazole. Journal of Heterocyclic Chemistry 5(5), 723-5 (English) 1968.
Kapetanovic, I.M.; Kupferberg, H.J. Nafimidone, an Imidazole Anticonvulsant, and Its Metabolite as Potent Inhibitors of Microsomal Metabolism of Phenytoin and Carbamazepine. Drug Metab. Dispos. (1984) 12(5):560-564.
Korte, A. et al. Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by N alpha-Methylhistamine. Biochem. Biophys. Res. Commun. (May 1990) 168(3):979-986.
Krause, M. et al. Medicinal Chemistry of Histamine H3 Receptor Agonists; In The Histamine H3 Receptor—A Target for New Drugs Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 175-196.
Lavrijsen, K. et al. Induction Potential of Antifungals Containing an Imidazole or Triazole Moiety. Biochem. Pharmacol. (1986) 35(11):1867-1878.
Leurs, R. et al. The Medicinal Chemistry and Therapeutic Potentials of Ligands of the Histamine H3 Receptor. Prog. Drug Res. (1995) 45:107-165.
Leurs, R. et al; “Therapeutic potential of histamine H3 recepto agonists and antagonitsts” Trends n Pharmacological sciences, Elsevier Trends Journal, Cambridge, BG, vol. 19, No. 5, May 1, 1998; pp. 177-184, XP004121095.
Lin, J.-S. et al. Involvement of Histaminergic Neurons in Arousal Mechanisms Demonstrated with H3-Receptor Ligands in the Cat. Brain Res. (1990) 523:325-330.
Linney, I.D. et al. Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists. J. Med. Chem. (2000) 43(12):2362-2370.
Lovenberg, T.W. et al. Cloning and Functional Expression of the Human Histamine H3 Receptor. Mol. Pharmacol. (1999) 55:1101-1107.
Lovenberg, T.W. et al. Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. (2000) 293(3):771-778.
Machidori, H. et al. Zucker Obese Rats: Defect in Brain Histamine Control of Feeding. Brain Res. (1992) 590:180-186.
McLeod, R.L. et al. Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist. Soc. Neuroscl. Abstr. (1996) 22:2010.
Meier, G. et al. Piperidino-Hydrocarbon Compounds as Novel Non-Imidazole Histamine H3-Receptor Antagonists. Bioorg. Med. Chem. (2002) 10:2535-2542.
Monti, J.M. et al. Effects of Selective Activation or Blockade of the Histamine H3 Receptor on Sleep and Wakefulness. Eur. J. Pharmacol. (1991) 205(3):283-287.
Morisset, S. et al. High Constitutive Activity of Native H3 Receptors Regulates Histamine Neurons in Brain. Nature (Dec. 2000) 408:860-864.
Oda, T. et al. Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes. J. Biol. Chem. (2000) 275(47):36781-36786.
Panula, P. et al. Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease. Soc. Neurosci. Abstr. (1995) 21:1977.
Phelps, M.E. Positron Emission Tomography Provides Molecular Imaging of Biological Processes. Proc. Natl. Acad. Sci. (2000) 97(16):9226-9233.
Phillips, J.G.; Ali, S.M. Medicinal Chemistry of Histamine H3 Receptor Antagonists: In The Histamine H3 Receptor—A Target for New Drugs Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 197-222.
Phillips, J.G. et al. Chapter 4, Recent Advances in Histamine H3Receptor Agents. Ann. Reports in Med. Chem., 31, 1998, pp. 31-40.
Rouleau, A. et al. Bioavailability, Antinociceptive and Antiinflammatory Properties of BP 2-94, a Histamine H3 Receptor Agonist Prodrug. J. Pharmacol. Exp. Ther. (1997) 281(3):1085-1094.
Sabbatini, Renato,M.E., The Cyclotron and PET, In Brain & Mind an electronic magazine about Neuroscience [online], Mar. 1997. Retrived from the internet, <http:www.epub.org.br/cm
01/pet/petcyclo.htm.
Schlicker, E.; Marr, I. The Moderate Affinity of Clozapine at H3 Receptors is Not Shared by Its Two Major Metabolites and by Structurally Related and Unrelated Atypical Neuroleptics. Naunyn-Schmiedebergs's Arch. Pharmacol. (1996) 353:290-294.
Sheets, J.J.; Mason. J.I. Ketoconazole: a Potent Inhibitor of Cytochrome P-450-Dependent Drug Metabolism in Rat Liver. Drug Metab. Dispos. (1984) 12(5):603-606.
Stark, H. et al. Developments of Histamine H3-Receptor Antagonists. Drugs Future (1996) 21(5):507-520.
Tozer, M.J., et al.: “From Histamine to Imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3 receptor antagonists”; Bioorganic & Medicinal CHemistry Letters, OXFORD, GB. vol. 9, No. 13, Jul. 5, 1999, pp. 1825-1830, XP004168846.
Tozer, M.J.; Kalin
Apodaca Richard L.
Dvorak Curt A.
Shah Chandravadan R.
Xiao Wei
Chang Celia
Janssen Pharmaceutica N.V.
LandOfFree
Phenylpiperidines and phenylpyrrolidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylpiperidines and phenylpyrrolidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylpiperidines and phenylpyrrolidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3860050